← Back to Search

Local Anesthetic

Liposomal bupivacaine for Benign Tumors

Phase 4
Waitlist Available
Research Sponsored by Samaritan Health Services
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
All benign soft tissue tumors greater than one cubic cm
Adults 18 years and older
Timeline
Screening 3 weeks
Treatment Varies
Follow Up first 7 days postoperatively
Awards & highlights

Study Summary

This study is evaluating whether a drug called Exparel can improve pain and functional outcomes for patients who have had a benign soft tissue tumor resection.

Eligible Conditions
  • Benign Tumors

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~first 7 days postoperatively
This trial's timeline: 3 weeks for screening, Varies for treatment, and first 7 days postoperatively for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Opioid Use
Secondary outcome measures
Pain Score
Other outcome measures
Musculoskeletal Tumor Society Score (MSTS score)

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: experimentalExperimental Treatment1 Intervention
Exparel group
Group II: controlActive Control1 Intervention
plain bupivacaine
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Bupivacaine
FDA approved

Find a Location

Who is running the clinical trial?

Samaritan Health ServicesLead Sponsor
3 Previous Clinical Trials
80 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~31 spots leftby Mar 2025